{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:28:11Z","timestamp":1794745691939,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","award":["Progetto Prama"],"award-info":[{"award-number":["Progetto Prama"]}],"id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","award":["Fondi Ateneo"],"award-info":[{"award-number":["Fondi Ateneo"]}],"id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","award":["Fondi Ateneo"],"award-info":[{"award-number":["Fondi Ateneo"]}],"id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","award":["Fondi Ateneo"],"award-info":[{"award-number":["Fondi Ateneo"]}],"id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"publisher","award":["Fondi Ateneo"],"award-info":[{"award-number":["Fondi Ateneo"]}],"id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002283","name":"Alzheimer's Research UK","doi-asserted-by":"publisher","award":["ARUK-PG2019B-020"],"award-info":[{"award-number":["ARUK-PG2019B-020"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Soluble A\u03b2 oligomers are regarded as major neurotoxic agents in Alzheimer\u2019s disease. Several monoclonal antibodies have been developed to target A\u03b2 oligomers, but most of them show limited specificity binding also to monomers and fibrils. To generate an antibody with high specificity for the oligomers, we aimed to increase the efficiency and sensitivity of a human VH\u2013derived A\u03b2-oligomer-specific single domain antibody, called DesAb-O. We engineered a dimeric DesAb-O variant, DiDesAb-O, which showed significantly higher binding affinity for A\u03b2 oligomers as compared to the monomeric sdAb. DiDesAb-O selectively detected A\u03b2\n                    <jats:sub>42<\/jats:sub>\n                    oligomers not only in vitro and in cultured cells using synthetic preparations, but also in the cerebrospinal fluid from Alzheimer\u2019s patients. Moreover, it inhibited the binding of these toxic species to cellular membranes and neutralized their neurotoxicity both in cells and in patient-derived cerebrospinal fluid at lower concentrations compared to DesAb-O. These results indicate that rational dimerization of single-domain antibodies can substantially enhance target engagement and functional efficacy, providing a promising strategy for the development of improved diagnostic and therapeutic molecules for Alzheimer\u2019s disease.\n                  <\/jats:p>","DOI":"10.1038\/s42003-026-09740-6","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:37:50Z","timestamp":1774629470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Engineering a dimeric single-domain antibody for improved detection and neutralization of amyloid-\u03b2 oligomers"],"prefix":"10.1038","volume":"9","author":[{"given":"Liliana","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devkee M.","family":"Vadukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-6288","authenticated-orcid":false,"given":"Alessandra","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-5085","authenticated-orcid":false,"given":"Pasquale","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-7737","authenticated-orcid":false,"given":"Cristina","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9856-6843","authenticated-orcid":false,"given":"Roberta","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-4420","authenticated-orcid":false,"given":"Francesco A.","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"9740_CR1","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. J. Alzheimers Assoc. 20, 3708\u20133821 (2024).","DOI":"10.1002\/alz.13809"},{"key":"9740_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).","journal-title":"EMBO Mol. Med."},{"key":"9740_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 14, 399\u2013415 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"9740_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol."},{"key":"9740_CR5","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"9740_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt, L. et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. J. Alzheimers Assoc. 15, 888\u2013898 (2019).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"9740_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","volume":"483","author":"J Nunan","year":"2000","unstructured":"Nunan, J. & Small, D. H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 483, 6\u201310 (2000).","journal-title":"FEBS Lett."},{"key":"9740_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom, G. S. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505\u2013508 (2014).","journal-title":"JAMA Neurol."},{"key":"9740_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486\u2013489 (2003).","journal-title":"Science"},{"key":"9740_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova, I., Karran, E. & De Strooper, B. The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349\u2013357 (2012).","journal-title":"Nat. Neurosci."},{"key":"9740_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","volume":"15","author":"DJ Selkoe","year":"2019","unstructured":"Selkoe, D. J. Alzheimer disease and aducanumab: adjusting our approach. Nat. Rev. Neurol. 15, 365\u2013366 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"9740_CR12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/biomedicines10071743","volume":"10","author":"BA Gutierrez","year":"2022","unstructured":"Gutierrez, B. A. & Limon, A. Synaptic disruption by soluble oligomers in patients with Alzheimer\u2019s and Parkinson\u2019s disease. Biomedicines 10, 1743 (2022).","journal-title":"Biomedicines"},{"key":"9740_CR13","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong, Y. et al. Alzheimer\u2019s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417\u201310422 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9740_CR14","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1021\/bi1016233","volume":"49","author":"CA Lasagna-Reeves","year":"2010","unstructured":"Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Mu\u00f1oz, M. J., Jackson, G. R. & Kayed, R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039\u201310041 (2010).","journal-title":"Biochemistry"},{"key":"9740_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.tips.2013.03.002","volume":"34","author":"F Hefti","year":"2013","unstructured":"Hefti, F. et al. The case for soluble A\u03b2 oligomers as a drug target in Alzheimer\u2019s disease. Trends Pharmacol. Sci. 34, 261\u2013266 (2013).","journal-title":"Trends Pharmacol. Sci."},{"key":"9740_CR16","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage, M. J. et al. A sensitive a\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J. Neurosci. J. Soc. Neurosci. 34, 2884\u20132897 (2014).","journal-title":"J. Neurosci. J. Soc. Neurosci."},{"key":"9740_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1267\/ahc.23-00058","volume":"56","author":"I Tooyama","year":"2023","unstructured":"Tooyama, I. et al. Visualization of amyloid oligomers in the brain of patients with Alzheimer\u2019s disease. Acta Histochem. Cytochem. 56, 87\u201394 (2023).","journal-title":"Acta Histochem. Cytochem."},{"key":"9740_CR18","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The amyloid-\u03b2 oligomer hpothesis: beginning of the third decade. J. Alzheimers Dis. 64, S567\u2013S610 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"9740_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/09168451.2014.940275","volume":"78","author":"K Murakami","year":"2014","unstructured":"Murakami, K. Conformation-specific antibodies to target amyloid \u03b2 oligomers and their application to immunotherapy for Alzheimer\u2019s disease. Biosci. Biotechnol. Biochem. 78, 1293\u20131305 (2014).","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"9740_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug Discov. 21, 306\u2013318 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9740_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"9740_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"9740_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"9740_CR24","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/alz.13755","volume":"20","author":"T Chen","year":"2024","unstructured":"Chen, T. et al. Results from the long-term extension of PRIME: a randomized phase 1b trial of aducanumab. Alzheimers Dement. J. Alzheimers Assoc. 20, 3406\u20133415 (2024).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"9740_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"9740_CR26","first-page":"5","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings, J., Osse, A. M. L., Cammann, D., Powell, J. & Chen, J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs Clin. Immunother. Biopharm. Gene Ther. 38, 5\u201322 (2024).","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"9740_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"9740_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molimm.2008.09.008","volume":"46","author":"P Lafaye","year":"2009","unstructured":"Lafaye, P., Achour, I., England, P., Duyckaerts, C. & Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 46, 695\u2013704 (2009).","journal-title":"Mol. Immunol."},{"key":"9740_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"9740_CR30","doi-asserted-by":"publisher","first-page":"632687","DOI":"10.3389\/fimmu.2021.632687","volume":"12","author":"C Ackaert","year":"2021","unstructured":"Ackaert, C. et al. Immunogenicity risk profile of nanobodies. Front. Immunol. 12, 632687 (2021).","journal-title":"Front. Immunol."},{"key":"9740_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04987-1","volume":"22","author":"N De Leiris","year":"2024","unstructured":"De Leiris, N. et al. A single-domain antibody for the detection of pathological tau protein in the early stages of oligomerization. J. Transl. Med. 22, 163 (2024).","journal-title":"J. Transl. Med."},{"key":"9740_CR32","first-page":"2825","volume":"58","author":"J Baselga","year":"1998","unstructured":"Baselga, J., Norton, L., Albanell, J., Kim, Y. M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825\u20132831 (1998).","journal-title":"Cancer Res."},{"key":"9740_CR33","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M708536200","volume":"283","author":"PA Barthelemy","year":"2008","unstructured":"Barthelemy, P. A. et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283, 3639\u20133654 (2008).","journal-title":"J. Biol. Chem."},{"key":"9740_CR34","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1073\/pnas.1422401112","volume":"112","author":"P Sormanni","year":"2015","unstructured":"Sormanni, P., Aprile, F. A. & Vendruscolo, M. Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc. Natl. Acad. Sci. USA 112, 9902\u20139907 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9740_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1700488","volume":"3","author":"FA Aprile","year":"2017","unstructured":"Aprile, F. A. et al. Selective targeting of primary and secondary nucleation pathways in A\u03b242 aggregation using a rational antibody scanning method. Sci. Adv. 3, e1700488 (2017).","journal-title":"Sci. Adv."},{"key":"9740_CR36","doi-asserted-by":"publisher","first-page":"13509","DOI":"10.1073\/pnas.1919464117","volume":"117","author":"FA Aprile","year":"2020","unstructured":"Aprile, F. A. et al. Rational design of a conformation-specific antibody for the quantification of A\u03b2 oligomers. Proc. Natl. Acad. Sci. USA 117, 13509\u201313518 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9740_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-023-01361-z","volume":"16","author":"A Bigi","year":"2024","unstructured":"Bigi, A. et al. A single-domain antibody detects and neutralises toxic A\u03b242 oligomers in the Alzheimer\u2019s disease CSF. Alzheimers Res. Ther. 16, 13 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"9740_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210879","volume":"35","author":"L Zhao","year":"2023","unstructured":"Zhao, L. et al. Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi-target therapy of Alzheimer\u2019s disease. Adv. Mater. 35, e2210879 (2023).","journal-title":"Adv. Mater."},{"key":"9740_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3463","volume":"40","author":"N McArthur","year":"2024","unstructured":"McArthur, N. et al. Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates. Biotechnol. Prog. 40, e3463 (2024).","journal-title":"Biotechnol. Prog."},{"key":"9740_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X., Zaro, J. L. & Shen, W.-C. Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357\u20131369 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9740_CR41","doi-asserted-by":"publisher","first-page":"W315","DOI":"10.1093\/nar\/gky497","volume":"46","author":"A Micsonai","year":"2018","unstructured":"Micsonai, A. et al. BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Res. 46, W315\u2013W322 (2018).","journal-title":"Nucleic Acids Res."},{"key":"9740_CR42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0003-2697(89)90602-7","volume":"182","author":"SC Gill","year":"1989","unstructured":"Gill, S. C. & von Hippel, P. H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319\u2013326 (1989).","journal-title":"Anal. Biochem."},{"key":"9740_CR43","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448\u20136453 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9740_CR44","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0076-6879(99)09027-8","volume":"309","author":"DG Myszka","year":"1999","unstructured":"Myszka, D. G., Wood, S. J. & Biere, A. L. Analysis of fibril elongation using surface plasmon resonance biosensors. Methods Enzymol. 309, 386\u2013402 (1999).","journal-title":"Methods Enzymol."},{"key":"9740_CR45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00216-015-9172-6","volume":"408","author":"P Palladino","year":"2016","unstructured":"Palladino, P., Aura, A. M. & Spoto, G. Surface plasmon resonance for the label-free detection of Alzheimer\u2019s \u03b2-amyloid peptide aggregation. Anal. Bioanal. Chem. 408, 849\u2013854 (2016).","journal-title":"Anal. Bioanal. Chem."},{"key":"9740_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0968-0004(99)01445-0","volume":"24","author":"CM Dobson","year":"1999","unstructured":"Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329\u2013332 (1999).","journal-title":"Trends Biochem. Sci."},{"key":"9740_CR47","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/1567205017666201109093848","volume":"17","author":"A Bigi","year":"2020","unstructured":"Bigi, A., Loffredo, G., Cascella, R. & Cecchi, C. Targeting pathological amyloid aggregates with conformation-sensitive antibodies. Curr. Alzheimer Res. 17, 722\u2013734 (2020).","journal-title":"Curr. Alzheimer Res."},{"key":"9740_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21937-3","volume":"12","author":"R Cascella","year":"2021","unstructured":"Cascella, R. et al. The release of toxic oligomers from \u03b1-synuclein fibrils induces dysfunction in neuronal cells. Nat. Commun. 12, 1814 (2021).","journal-title":"Nat. Commun."},{"key":"9740_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","volume":"17","author":"Y Wouters","year":"2020","unstructured":"Wouters, Y., Jaspers, T., De Strooper, B. & Dewilde, M. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS 17, 62 (2020).","journal-title":"Fluids Barriers CNS"},{"key":"9740_CR50","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/biom11081131","volume":"11","author":"E Ruiz-L\u00f3pez","year":"2021","unstructured":"Ruiz-L\u00f3pez, E. & Schuhmacher, A. J. Transportation of single-domain antibodies through the blood-brain barrier. Biomolecules 11, 1131 (2021).","journal-title":"Biomolecules"},{"key":"9740_CR51","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/pharmaceutics14071452","volume":"14","author":"A Yogi","year":"2022","unstructured":"Yogi, A. et al. Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor. Pharmaceutics 14, 1452 (2022).","journal-title":"Pharmaceutics"},{"key":"9740_CR52","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jmb.2008.09.068","volume":"384","author":"A Zameer","year":"2008","unstructured":"Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V. & Sierks, M. R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J. Mol. Biol. 384, 917\u2013928 (2008).","journal-title":"J. Mol. Biol."},{"key":"9740_CR53","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.neurobiolaging.2010.09.020","volume":"33","author":"S Kasturirangan","year":"2012","unstructured":"Kasturirangan, S. et al. Nanobody specific for oligomeric \u03b2-amyloid stabilizes nontoxic form. Neurobiol. Aging 33, 1320\u20131328 (2012).","journal-title":"Neurobiol. Aging"},{"key":"9740_CR54","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/protein\/gzt025","volume":"26","author":"RM Nisbet","year":"2013","unstructured":"Nisbet, R. M. et al. Central amyloid-\u03b2-specific single chain variable fragment ameliorates A\u03b2 aggregation and neurotoxicity. Protein Eng. Des. Sel. PEDS. 26, 571\u2013580 (2013).","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"9740_CR55","doi-asserted-by":"publisher","first-page":"978513","DOI":"10.3389\/fimmu.2022.978513","volume":"13","author":"F Zheng","year":"2022","unstructured":"Zheng, F. et al. Applications of nanobodies in brain diseases. Front. Immunol. 13, 978513 (2022).","journal-title":"Front. Immunol."},{"key":"9740_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","volume":"243","author":"T Li","year":"2016","unstructured":"Li, T. et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J. Control. Release Soc. 243, 1\u201310 (2016).","journal-title":"J. Control. Release Soc."},{"key":"9740_CR57","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1111\/febs.15809","volume":"289","author":"MA Rossotti","year":"2022","unstructured":"Rossotti, M. A., B\u00e9langer, K., Henry, K. A. & Tanha, J. Immunogenicity and humanization of single-domain antibodies. FEBS J. 289, 4304\u20134327 (2022).","journal-title":"FEBS J."},{"key":"9740_CR58","doi-asserted-by":"publisher","first-page":"e17665","DOI":"10.1371\/journal.pone.0017665","volume":"6","author":"A Hultberg","year":"2011","unstructured":"Hultberg, A. et al. Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS ONE 6, e17665 (2011).","journal-title":"PLoS ONE"},{"key":"9740_CR59","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.1128\/JVI.03178-13","volume":"88","author":"FM Cardoso","year":"2014","unstructured":"Cardoso, F. M. et al. Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge. J. Virol. 88, 8278\u20138296 (2014).","journal-title":"J. Virol."},{"key":"9740_CR60","doi-asserted-by":"publisher","first-page":"100241","DOI":"10.1074\/jbc.RA120.015327","volume":"296","author":"P He","year":"2021","unstructured":"He, P., Schulz, P. & Sierks, M. R. A conformation-specific antibody against oligomeric \u03b2-amyloid restores neuronal integrity in a mouse model of Alzheimer\u2019s disease. J. Biol. Chem. 296, 100241 (2021).","journal-title":"J. Biol. Chem."},{"key":"9740_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1471-4159.2006.04157.x","volume":"100","author":"MP Lambert","year":"2007","unstructured":"Lambert, M. P. et al. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100, 23\u201335 (2007).","journal-title":"J. Neurochem."},{"key":"9740_CR62","doi-asserted-by":"publisher","first-page":"8920","DOI":"10.3390\/ijms21238920","volume":"21","author":"ALB Bitencourt","year":"2020","unstructured":"Bitencourt, A. L. B., Campos, R. M., Cline, E. N., Klein, W. L. & Sebollela, A. Antibody fragments as tools for elucidating structure-toxicity relationships and for diagnostic\/therapeutic targeting of neurotoxic amyloid oligomers. Int. J. Mol. Sci. 21, 8920 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9740_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66970-6","volume":"14","author":"JR Haynes","year":"2024","unstructured":"Haynes, J. R. et al. Targeting soluble amyloid-beta oligomers with a novel nanobody. Sci. Rep. 14, 16086 (2024).","journal-title":"Sci. Rep."},{"key":"9740_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57143-x","volume":"10","author":"A Abelein","year":"2020","unstructured":"Abelein, A. et al. High-yield production of amyloid-\u03b2 peptide enabled by a customized spider silk domain. Sci. Rep. 10, 235 (2020).","journal-title":"Sci. Rep."},{"key":"9740_CR65","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1021\/jacs.3c03212","volume":"145","author":"DM Vadukul","year":"2023","unstructured":"Vadukul, D. M. et al. \u03b1-synuclein aggregation is triggered by oligomeric amyloid-\u03b2 42 via heterogeneous primary nucleation. J. Am. Chem. Soc. 145, 18276\u201318285 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"9740_CR66","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1038\/nprot.2006.229","volume":"1","author":"NJ Greenfield","year":"2006","unstructured":"Greenfield, N. J. Determination of the folding of proteins as a function of denaturants, osmolytes or ligands using circular dichroism. Nat. Protoc. 1, 2733\u20132741 (2006).","journal-title":"Nat. Protoc."},{"key":"9740_CR67","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.1021\/bi00421a014","volume":"27","author":"MM Santoro","year":"1988","unstructured":"Santoro, M. M. & Bolen, D. W. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl .alpha.-chymotrypsin using different denaturants. Biochemistry 27, 8063\u20138068 (1988).","journal-title":"Biochemistry"},{"key":"9740_CR68","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal. Biochem."},{"key":"9740_CR69","doi-asserted-by":"publisher","first-page":"e86720","DOI":"10.1371\/journal.pone.0086720","volume":"9","author":"C Capitini","year":"2014","unstructured":"Capitini, C. et al. TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLoS ONE 9, e86720 (2014).","journal-title":"PLoS ONE"},{"key":"9740_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-024-00405-0","volume":"13","author":"A Bigi","year":"2024","unstructured":"Bigi, A. et al. Putative novel CSF biomarkers of Alzheimer\u2019s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort. Transl. Neurodegener. 13, 14 (2024).","journal-title":"Transl. Neurodegener."},{"key":"9740_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/febs.16579","volume":"290","author":"A Bigi","year":"2023","unstructured":"Bigi, A. et al. Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid-\u03b2 oligomers through endocytic internalization of NMDA receptors. FEBS J. 290, 112\u2013133 (2023).","journal-title":"FEBS J."},{"key":"9740_CR72","doi-asserted-by":"publisher","unstructured":"Napolitano, L. et al. Source data for: engineering a dimeric single-domain antibody for improved detection and neutralization of amyloid-\u03b2 oligomers. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.18339814 (2026).","DOI":"10.5281\/zenodo.18339814"},{"key":"9740_CR73","doi-asserted-by":"crossref","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","DOI":"10.1038\/s41586-024-07487-w"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09740-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09740-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:03:32Z","timestamp":1783105412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09740-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9740"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09740-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"896"}}